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1. Introduction 
A potential drug-drug interaction (DDI) is related to the possibility of a drug to alter the 
effect of another drug simultaneously administered. It can occur before or after drug 
administration (Almeida et al., 2007). DDI are considered predictable and thus avoidable 
and manageable (Cruciol-Souza et al., 2006).  
Many of these interactions have slow onset clinical manifestations that can be diagnosed as 
new diseases and handled wrongly (Correr et al., 2007). Drug interactions are estimated to 
occur between 3% and 5% in patients to whom few drugs are prescribed and 20% among 
those who use 10 to 20 drugs simultaneously (Ferreira Sobrinho et al., 2006). The incidence 
of drug interactions is directly proportional to the increase in the number of drugs 
prescribed (Matos et al., 2009). It is known that a prescription containing eight or more 
drugs will present at least one interaction (Almeida et al., 2007).  
Drug interactions incidence in Intensive Care Unit (ICU) is higher than hospital rates in 
general probably due to patient disease severity admitted in this unit (Almeida et al., 2007). 
ICU patients usually need great number of administered drugs and they are under risk of 
44.3% to 95.0% of potential drug interactions occurrence (Sierra et al., 1997; Meneses & 
Monteiro, 2000). New drugs availability and prescription of fixed drug combinations 
difficult potential interactions identification (Trato, 2005). Thereby, this study aimed to 
discuss the risk of DDI in medical prescriptions of adult inpatients in ICU under use of 
antihypertensive drugs.  
Commonly used drugs in ICU are vasoconstrictors and cardiotonic agents, antimicrobials, 
coronary vasodilators, direct vasodilators, antisecretory drugs, anticoagulants, sedatives-
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hypnotics agents, antiemetics, antidiabetics agents, analgesics-antipyretics and 
antiinflammatory drugs. 
Micromedex® DrugReax® System (Klasco, 2011) is one of the most used database to 
describe interactions. The DrugReax System contains a dictionary of more than 8,000 unique 
drug terms. This system distinguishes trade names from equivalent generic names and it 
analyses specific drug instead of drug class. This database provides information about 
clinical consequences or adverse drug reactions that could result from a DDI, describe the 
interaction mechanism and classifies onset, severity and scientific knowledge of adverse 
reactions caused by the DDI.  
Onset is classified as rapid (effects expected within 24 hours of drug administration), 
delayed (effects not expected to appear within the first 24 hours following drug 
administration) or unknown (effects expected to appear any time after drug administration).  
Severity is classified as minor (limited clinical effects including increased frequency or 
severity of adverse effects and generally no major alteration in therapy), moderate 
(exacerbation of patient’s condition and/or an alteration in therapy), major (life-threatening 
interaction and/or medical intervention to minimize or prevent serious adverse effects) or 
contraindicated (life-threatening interaction).  
Scientific knowledge is classified considering how well DDI is documented in the literature 
that means excellent (controlled studies clearly established the existence of the interaction), 
good (documentation strongly suggests the interaction exists but well-controlled studies are 
lacking), fair (available documentation is poor but pharmacologic considerations lead 
clinicians to suspect about interaction existence or documentation is good for a 
pharmacologically similar drug) or unknown (no documentation about the interaction).  
Table 1 presents the classification of DDI involving antihypertensive and the most frequent 
used drugs in ICU.  
 
Antihypertensives Drug Classes Severity Onset 
Scientific 
knowledge
DDI Outcome 
Calcium channel 
blockers 
Histamine H2-
antagonists 
(cimetidine)  
Moderate Rapid Good Increased concentrations of 
calcium channel blockers 
and possible cardiovascular 
toxicity 
 Benzodiazepinics Moderate Rapid Good Increased/prolonged 
sedation 
Opioid analgesics Major Rapid Good Severe hypotension and an  
increased risk of respiratory 
depression  
Antifungals Moderate Delayed Good Increased calcium channel 
blockers concentrations and 
toxicity (dizziness, 
hypotension, flushing, 
headache, peripheral 
edema). 
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Antihypertensives Drug Classes Severity Onset 
Scientific 
knowledge
DDI Outcome 
Glucocorticoids Moderate Rapid Good Increased glucocorticoids 
concentrations and 
enhanced adrenal-
suppressant effects 
Calcium channel 
blockers 
Moderate Rapid Good Toxicity (headache, 
peripheral edema, 
hypotension, tachycardia) 
Beta-blocker 
drugs 
Major Rapid Good Increased risk of 
hypotension, bradycardia, 
atrioventricular conduction 
disturbances 
Alpha 1-
adrenergic 
blockers 
Moderate Rapid Fair Hypotension 
Alpha 2-
adrenergic 
agonistic drug 
Major Not 
specified
Good Increased incidence of sinus 
bradycardia requiring 
hospitalization and insertion 
of a pacemaker 
Beta-blockers Calcium channel 
blockers 
Moderate Rapid Good Hypotension and/or 
bradycardia 
 Sympathomimetics Major Rapid Excellent Hypertension, bradycardia 
and resistance to 
epinephrine in anaphylaxis 
Hypoglycemic Moderate Delayed Good Hypoglycemia, 
hyperglycemia or 
hypertension 
Alpha 1-
adrenergic 
blockers 
Moderate Rapid Good Exaggerated hypotensive 
response to the first dose of 
the alpha blocker 
Direct 
vasodilators 
Moderate Delayed Fair Increased risk of 
propranolol adverse effects 
(bradycardia, fatigue, 
bronchospasm) 
Lopp diuretics Moderate Rapid Fair Hypotension, bradycardia 
Thiazide diuretics Moderate Delayed Fair Hyperglycemia, 
hypertriglyceridemia 
Fluoroquinolone Minor Delayed Fair Bradycardia, hypotension 
Lopp diuretics Nonsteroidal 
antiinflammatory 
agents
Moderate Delayed Good Decreased diuretic and 
antihypertensive efficacy 
 Beta-blocker 
drugs
Moderate Rapid Fair Hypotension, bradycardia 
Glucocorticoids Moderate Delayed Fair Hypokalemia 
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Antihypertensives Drug Classes Severity Onset 
Scientific 
knowledge
DDI Outcome 
Direct 
vasodilators 
Minor Rapid Good Enhanced diuretic response 
to loop diuretic 
Potassium-sparing 
diuretics 
Nonsteroidal 
antiinflammatory 
agents 
Moderate Delayed Good Reduced diuretic 
effectiveness, hyperkalemia, 
or possible nephrotoxicity 
 Angiotensin 
converting 
enzyme inhibitors
Moderate Delayed Good Hyperkalemia 
Angiotensin II 
Receptor Blockers
Moderate Delayed Fair Hyperkalemia 
Thiazide diuretics Glucocorticoids Moderate Delayed Fair Hypokalemia and 
subsequent cardiac 
arrhythmias 
 Nonsteroidal 
antiinflammatory 
agents 
Moderate Delayed Good Decreased diuretic and 
antihypertensive efficacy 
Beta-blockers Moderate Delayed Fair Hyperglycemia, 
hypertriglyceridemia 
Angiotensin 
converting  
enzyme  
inhibitors 
Nonsteroidal 
antiinflammatory 
agents 
Moderate Not 
specified
Excellent Decreased antihypertensive 
efficacy 
 Lopp diuretics Moderate Rapid Good Postural hypotension  
(first dose) 
Thiazide diuretics Moderate Rapid Good Postural hypotension  
(first dose) 
Catecholamine 
synthesis or 
release blockers 
Beta-blockers Moderate Rapid Fair Exaggerated hypertensive 
response, tachycardia, or 
arrhythmias during 
physiologic stress or 
exposure to exogenous 
catecholamines 
 Oxazolidinone Contraindicated Rapid Good Hypertensive crisis 
(headache, palpitation, neck 
stiffness) 
Direct vasodilators Lopp diuretics Minor Rapid Good Enhanced diuretic response 
to loop diuretic 
Alpha 2-
adrenergic 
blockers 
Beta-blockers Major Not 
specified
Fair Increased risk of sinus 
bradycardia; exaggerated 
clonidine withdrawal 
response  
(acute hypertension) 
Table 1. Classification of DDI involving antihypertensive drugs in medical prescriptions of 
adult inpatients in ICU 
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2. DDI of major severity 
The combination of calcium channel blockers with opioid analgesics is classified as major 
severity because it may result in severe hypotension and an increased risk of respiratory 
depression caused by fentanyl toxicity. For example, diltiazem is a moderate CYP3A4 
inhibitor and fentanyl is a CYP3A4 substrate. The concurrent use may result in increased 
fentanyl plasma levels and fatal respiratory depression. Caution is necessary if these agents 
are given concurrently and use the lowest possible fentanyl dose. Patient should be carefully 
monitored for an extended period of time for fentanyl adverse events. Any dosage increases 
to either medication should be made carefully. 
Calcium channel blockers and beta-blocker drugs co-administration is also classified as 
major severity because it may result in an increased risk of hypotension, bradycardia, 
atrioventricular conduction disturbances. If concurrent therapy is required, cardiac function 
and blood pressure should be carefully monitored, particularly in patients predisposed to 
heart failure. A dosage adjustment for hepatically metabolized beta blockers may be 
required. 
The combination of calcium channel blockers with alpha 2-adrenergic agonistic drug is 
classified as major severity because it may result in increased incidence of sinus bradycardia 
requiring hospitalization and insertion of a pacemaker. Therefore, heart rate should be 
monitored when clonidine and verapamil or diltiazem are given concurrently.  
The abrupt discontinuation of vasodilators may lead to a hyper-adrenergic attack causing 
acute myocardial infarction, stroke and/or other complications due to rebound 
vasoconstriction. This effect is known as antihypertensive drugs withdrawal. The most 
commonly drugs involved in this effect are the beta-blockers, centrally acting agents, direct 
vasodilators and calcium channel blockers (Kirk & Johnson, 1995).  
Concomitant use of beta-blockers and clonidine provide the rebound effect after abrupt 
withdrawal of therapy. Clonidine by an agonistic effect on presynaptic alpha-2 receptors 
decreases noradrenaline release from postganglionic sympathetic neurons. It is an excess of 
catecholamines in the synaptic clefts when the administration of clonidine is interrupted 
and this catecholamines are available for binding to the alpha and beta receptors. However, 
if the beta receptor, auxiliar in vasodilation, is blocked, the alpha effects are not 
counterbalanced. The result is vasoconstriction, rebound hypertension and risk of coronary 
and cerebral vasospasm. It is recommended that in patients who are on beta blockers and 
clonidine, the drug should be withdrawn gradually to avoid this adverse drug reaction. 
Moreover, the use of clonidine and beta-blocker raises the risk of sinus bradycardia 
(Goodman & Gilman, 2011). 
The concurrent use of beta-blocker and sympathomimetic drugs should be avoided because 
it may result in hypertension, bradycardia and resistance to epinephrine in anaphylaxis. 
However, if concomitant therapy is necessary, patient should be carefully monitored for 
severe and prolonged hypertension. Glucagon has positive inotropic and chronotropic 
effects that are independent of adrenergic receptors. The use of this agent is of great 
importance in patients on beta blockers which are affected by an anaphylactic reaction. 
Glucagon increases cardiac output and coronary perfusion, decreasing myocardial hypoxia 
and a possible secondary cardiogenic shock (Lieberman, 1998). 
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Alpha 2-adrenergic blockers and beta-blockers may result in increased risk of sinus 
bradycardia; exaggerated clonidine withdrawal response (acute hypertension). Monitor heart 
rate when clonidine and atenolol are given concurrently. Patients to be withdrawn from 
clonidine who are concomitantly receiving a beta blocking agent, such as atenolol, should be 
withdrawn from the beta blocker several days before the gradual discontinuation of clonidine 
to avoid an excessive rise in blood pressure. In the case of a hypertensive crisis following 
discontinuation of clonidine, IV phentolamine or oral clonidine can be used to reverse the 
excessive rise in blood pressure. Patients to be withdrawn from clonidine who are 
concomitantly receiving a beta blocking agent should be monitored carefully for hypertension. 
3. Catecholamine synthesis or release blockers and oxazolidinone 
The severity of the most frequent used drugs in ICU is moderate to minor. However, the 
combination of catecholamine synthesis or release blockers with oxazolidinone is 
contraindicated because it may result in hypertensive crisis, causing headache, palpitation and 
neck stiffness. Hypertension due to drugs can cause increase of blood pressure level, reduction 
of antihypertensive drug effectiveness or the worsening of a pre-existing hypertension.  
Linezolida is an antibiotic used to treat infections caused by gram-positive bacteria but this 
drug is also a non-selective and reversible inhibitor of monoamine oxidase (MAO). The 
inhibitors of this enzyme block the oxidative deamination of three biogenic amines which 
are norepinephrine, dopamine and 5-hydroxytryptamine. When monoamine oxidase 
inhibitors (MAOI) are associated with sympathomimetic drugs or foods containing 
tyramine, hypertensive crisis may occur (Fuzikawa et al., 1999). The hypertensive crises are 
life-threatening and can also cause damage to susceptible organs as heart, brain and kidneys 
(Plavnik, 2002). 
4. Calcium channel blockers and histamine H2-antagonists 
The co-administration of calcium channel blockers and some histamine H2-antagonists, as 
cimetidine, result in increased concentrations of calcium channel blockers and possible 
cardiovascular toxicity. This effect happens because of Cytochrome P (CYP) 450 inhibition.  
The Cytochrome P (CYP) 450 is a superfamily of hemoproteins that play an important role 
in the metabolism of steroid hormones, fatty acids and many drugs. Many agents used for 
management of cardiovascular diseases are substrates, inhibitors or inducers of CYP450 
enzymes. When two agents that are substrates, inhibitors or inducers of CYP450 are 
administered together, drug interactions with significant clinical consequences may occur 
(Cheng et al., 2009). Monitoring cardiovascular response is necessary when the patient is in 
use of cimetidine and a calcium channel blocker. Dose reductions of up to 35% to 40% may 
be needed for diltiazem or nifedipine if co-administered with cimetidine. 
5. Antihypertensive and antiinflammatory agents 
5.1 Nonsteroidal antiinflammatory agents 
Nonsteroidal antiinflammatory drugs (NSAID) may block the antihypertensive effects of 
thiazide and loop diuretics, ┚-adrenergic blockers, ┙-adrenergic blockers and angiotensin-
www.intechopen.com
 
Drug Interaction Exposures in an Intensive Care Unit: Population Under Antihypertensive Use 
 
127 
converting enzyme inhibitors. It seems to happen by NSAID interference with 
prostaglandins synthesis which may thus limit the ability of antihypertensive drugs to 
control blood pressure. 
When concomitant use of loop diuretics and NSAID is required, patient should be 
monitored for diuretic efficacy and for signs of renal failure.  
Potassium-sparing diuretics and NSAID co-administration may also result in hyperkalemia 
or possible nephrotoxicity. If this combination is necessary, patient should be monitored for 
blood pressure, weight changes, urine output, potassium levels, creatinine levels, decreased 
effectiveness of the diuretic and hyperkalemia. 
In same way, when concurrently administration of thiazide diuretics and NSAID is 
necessary, blood pressure and weight should be monitored. It is important to follow the 
patient for signs of renal failure, including decreases in urine output and increased edema. 
Caution is recommended when prescribing NSAID to patients taking ACE inhibitors. When 
concomitant use is required, patient should be monitored for ACE inhibitor efficacy and for 
signs of renal failure. NSAID may also promote the development of hyperkalemia in 
association with ACE inhibitors as a result of deterioration of renal function. They are also 
responsible for reducing the antihypertensive effects of ACEI by interfering in the synthesis 
of prostaglandins. Probenicid reduces captopril renal excretion and increases its plasma 
concentration. On the other hand, aspirin and antiacids may decrease or abolish the 
antihypertensive efficacy of captopril (Gonzaga et al., 2009). 
The mechanism of the hypertensive effects caused by NSAID seems primarily to be related 
to their ability to block the cyclo-oxygenase pathway of arachidonic acid metabolism which 
results in decrease of prostaglandin formation. The prostaglandins are important in normal 
modulation of renal and systemic vascular dilatation, glomerular filtration, tubular secretion 
of salt and water reabsorption, adrenergic neurotransmission and the renin-angiotensin-
aldosterone system. Blockade of benef3ic effects of prostaglandins by NSAID results in 
complexes events which culminate in attenuation of many antihypertensive agents effects. 
The risk is greatest in the elderly, blacks and patients with low-renin hypertension. 
(Houston, 1991). 
Pharmacologically, it is thought that NSAID interact differently with antihypertensive 
drugs. However, the NSAID effects on newly initiated antihypertensive drug therapy 
remain unclear because few studies have included patients who were initially administered 
NSAID and then antihypertensives. Physiologically, the effects of renal prostaglandins on 
salt and water transport in the kidney are complementary to the actions of diuretics. 
Therefore, it is likely that the blocking of prostaglandins synthesis by NSAID attenuates the 
effect of diuretics. angiotensin-converting enzyme (ACE) inhibitors produce vasodilatation 
and lower blood pressure by inhibiting ACE which promotes the formation of angiotensin-2 
and aldosterone. Bradykinin is an autacoid that produces vasodilatation and further reduces 
blood pressure. Blocking ACE decreases the inhibition of bradykinin-induced 
vasodilatation. However, the vasodilatory properties of bradykinin that contribute to the 
antihypertensive properties of ACE inhibition appear to be mediated through local release 
of prostaglandins and are therefore susceptible to interference by NSAID (Ishiguro et al., 
2008). 
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5.2 Steroidal antiinflammatory agents 
Glucocorticoids may increase blood pressure by increasing the concentration of sodium-
potassium adenosine triphosphate in the cell membrane which could increase the 
concentration of extracellular sodium and therefore expand the plasma volume. Cortisol 
also stimulates the synthesis of mineralocorticoid aldosterone leading to sodium and water 
retention and, consequently, increased blood volume and cardiac output (Ortega et al., 1996; 
Brown, 2005). It also increases the sensitivity of the myocardium to endogenous 
catecholamine and increases the vascular response to endogenous vasopressors such as 
angiotensin II and norepinephrine (Ortega et al., 1996). In addition, glucocorticoids induce 
hepatic production of angiotensinogen resulting in an exacerbated response of the renin-
angiotensin-aldosterone system (Dukes, 1992). 
6. Beta-blockers and hypoglycemic drugs 
The use of beta-blockers and hypoglycemic may result in hypoglycemia, hyperglycemia or 
hypertension. If the use of a beta blocker is required in a diabetic patient, glucose should be 
carefully monitored. Cardioselective beta blockers (atenolol, metoprolol) cause less 
disturbance of glucose metabolism and less masking of hypoglycemic effects. Propranolol 
accounts for the majority of positive reports of interactions and should clearly be avoided.  
Hyperglycemia occurs frequently in critically ill patients and it is a marker of poor 
prognosis (Pitrowsky et al., 2009). The main complication of insulin therapy is 
hypoglycemia which is considered a potentially serious adverse event in these patients 
(Diener et al., 2006). The combination of a beta-blocker and insulin may impose a higher risk 
of blood glucose changes and lead to the development of hypoglycemia, hyperglycemia and 
hypertension.  
Beta-blockers may inhibit some of the normal physiologic response to hypoglycemia. 
Symptoms of hypoglycemia such as tremors and tachycardia may be absent, making it more 
difficult for patients to recognize an oncoming episode. In addition, multiple effects on 
glucose metabolism have been reported, usually with the noncardioselective beta-blockers 
(e.g., propranolol, pindolol, timolol) but occasionally also with relatively beta-1 selective 
agents (e.g., metoprolol). Specifically, inhibition of catecholamine-mediated glycogenolysis 
and glucose mobilization in association with beta-blockade can potentiate insulin-induced 
hypoglycemia in diabetics and delay the recovery of normal blood glucose levels. Prolonged 
and severe hypoglycemia may occur, although these events have rarely been reported. 
Significant increases in blood pressure and bradycardia can also occur during hypoglycemia 
in diabetics treated with insulin and beta-blockers due to antagonism of epinephrine's effect 
on beta-2 adrenergic receptors, which leads to unopposed alpha-adrenergic effects including 
vasoconstriction. Other effects reported with various beta-blockers include decreased 
glucose tolerance and decreased glucose-induced insulin secretion (Goodman & Gilman, 
2010).   
7. Conclusion 
The need of multiple drugs simultaneously used is common in the intensive care 
environment and contribute to the occurrence of drug interactions. The clinical 
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consequences of these interactions should be considered in order not to endanger ICU 
inpatients health once this population is under unfavorable conditions. 
The presence of drug interactions is a permanent risk in the ICU and not all DDI can be 
prevented. The use of software is mentioned in the literature as an important toll in 
reviewing prescriptions to identify interactions and reduce adverse events. Also, the 
continuing education of professionals involved in the processes of prescribing, dispensing 
and administering medicines as the main risk factors for drug interactions, the 
dissemination of information regarding the more frequent and important in clinical practice 
about drug interactions are instruments in the prevention of drug interactions. 
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authors of the chapters look from different angles to hypertension, sharing their new knowledge and
experience in the direction of deep understanding and more clarification of the disease providing an invaluable
resource not only for clinicians, but also for all medical sciences students and health providers.
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